autologous stem cell transplantation
autologous stem cell transplantation is a medical procedure with 34 clinical trials. Currently 6 active trials ongoing. Historical success rate of 76.2%.
Success Metrics
Based on 16 completed trials
Phase Distribution
Phase Distribution
10
Early Stage
14
Mid Stage
8
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
76.2%
16 of 21 finished
23.8%
5 ended early
6
trials recruiting
34
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
Autologous Stem Cell Transplantation in Chronic Lymphocytic Leukemia
Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia
High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma
Clinical Trials (34)
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
Autologous Stem Cell Transplantation in Chronic Lymphocytic Leukemia
Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia
High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma
Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Comparing ASCT Followed by Anti-BCMA CAR-T vs. ASCT Alone in NDMM Patients Eligible for ASCT
ASCT With Nivolumab in Patients With Multiple Myeloma
Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma
Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients
Impact of COVID-19 After Autologous Hematopoietic Stem Cell Transplantation in Sweden
Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma
A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma
R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma
Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma
Correlation Analysis of T-lymphocyte Subsets and Prognosis in Autologous Stem Cell Transplantation (ASCT) for Lymphoma
Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children
2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis
Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms
Stem Cell Transplantation in Ocular Lesions of Behcet's Disease
Drug Details
- Intervention Type
- PROCEDURE
- Total Trials
- 34